Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

OGT Enters Licensing Agreement for Twelve Colorectal Cancer Biomarkers

By Labmedica International staff writers
Posted on 27 Feb 2012
Oxford Gene Technology (OGT; Oxford, United Kingdom), provider of clinical genetics and diagnostic solutions, has entered into an exclusive licensing agreement with Inven2 (Oslo, Norway), the technology transfer office at Oslo University Hospital (OUS; Oslo, Norway) and University of Oslo (UiO; Oslo, Norway), for 12 promising colorectal cancer tissue biomarkers.

The DNA methylation biomarkers were developed in the laboratory of Prof. Ragnhild A. Lothe, in the department of Cancer Prevention, the Norwegian Radium Hospital, part of the Oslo University Hospital. As a result of the agreement OGT will be able to commercialize any test developed using these biomarkers and to sublicense the markers to other parties.

The results obtained in Prof. Lothe’s laboratory were validated by OGT, and demonstrated a sensitivity of 93% and specificity of 90% when using tissue biopsies. The efficacy of the biomarkers in blood and fecal samples is still being studied.

“This licensing agreement gives OGT exclusive access to genetic markers which are associated with colorectal cancer,” stated Dr. Mike Evans, CEO, of OGT. “We believe that developing tests that include these genetic markers will permit the earlier identification of patients at risk of this disease and allow for more timely diagnosis and clinical interventions.” Dr. Evans added, “The higher specificity of this new panel of markers could provide a more robust screening tool than the tests currently used, while eventually lowering overall costs, which would be of significant benefit for both patients and the clinicians using them.”

A robust preventive strategy for colorectal cancer that can stratify patients into appropriate screening or surveillance programs is lacking for early detection of cancer. Internationally, the chosen modality of colorectal cancer screening varies, with cost and availability of diagnostic resources likely to be the leading factors effecting program design.

OGT provides clinical genetics and diagnostic solutions to advance molecular medicine. The company supplies specific customized biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.

Related Links:
Oxford Gene Technology
Inven2
University of Oslo


KARL HECHT GMBH & CO KG
DIASYS DIAGNOSTIC SYSTEMS
77 ELEKTRONIKA

Channels

Genetic Tests

view channel

Padlock Probe Assay Rapidly Detects Cardiac Disease Gene Mutations

A recent paper described a novel next generation sequencing (NGS) assay for detecting cardiac disease gene mutations with improved accuracy, flexibility, turnaround time, and cost. By using double-stranded DNA probes (complementary long "padlock" probes or cLPPs), investigators at Stanford University (Palo Alto, CA,... Read more

Hematology

view channel
Image: Immunochemistry of bone marrow biopsy from an acute myeloid leukemia patient showing sheets of CD34 positive cells; corresponding bone marrow aspirate showed only 20% blasts (Photo courtesy of All India Institute of Medical Sciences).

Immunohistochemistry Assesses Early Response in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to prognosis and early response assessment has an established role as predictor of remission rate, and overall and disease-free survival.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.